Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy

Acta Paediatrica, International Journal of Paediatrics

Volumn 92, Issue 10, 2003, Pages 1205-1207

  Flidel Rimon, O ^a,b   Friedman, S ^a   Gradstein, S ^a   Bardenstein, R ^a   Shinwell, E S ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

3rd generation cephalosporins; Multidrug resistant Klebsiella; Nosocomial infection; Piperacillin tazobactam

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC THERAPY; ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; EMPIRICISM; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION RATE; KLEBSIELLA; NEWBORN SEPSIS; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFANT, NEWBORN; INFECTION CONTROL; ISRAEL; KLEBSIELLA INFECTIONS; PENICILLANIC ACID; PIPERACILLIN;

EID: 0142125325     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1080/08035250310005297     Document Type: Article

References (9)

1. Makhoul IR, Sujov P, Smolkin T, Lusky A, Reichman Bin collaboration with the Israel Neonatal Network. Epidemiological, clinical, and microbiological characteristics of late-onset sepsis among very low birth weight infants in Israel: a national survey. Pediatrics 2002; 109: 34-9.
2. Royle J, Haltz S, Eagles G, Gilbert G, Dalton D, Jelfs P, et al. Outbreak of extended spectrum β-lactamase producing Klebsiella in a neonatal unit. Arch Dis Child Fetal Neonatal 1999; 80: f64-8.
3. Meyer KS, Urban C, Egan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann of Intern Med 1993; 119: 353-8.
4. National Committee for Clinical Laboratory Standards document M100-SB 940 West valley road. Suite 1400. Wayne Pennsylvania. PA 19087 USA 1998.
5. Quinn JP. Clinical significance of extended-spectrum beta-lactamase. Eur J Clin Microbiol Infect Dis 1994; Suppl 1: 39-42.
6. Piroth L, Aube H, Doise JM, Martin MV. Spread of extended-spectrum β-lactamase producing Klebsiella pneumoniae: are β-lactamase inhibitors of therapeutic values? Clin Infect Dis 1998; 27: 76-80.
7. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-8.
8. Urban C, Mariano N, Rahanan N, Queenam AM, Montenegro D, Bush K, et al. Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins. Microb Drug Resis 2000; 6: 279-303.
9. Pillay T, Pillay DG, Adhikari M, Sturm AW. Piperacillin/tazobactam in treatment of Klebsiella pneumoniae infection in neonates. Am J Perinatol 1998; 15: 47-51.